Abstract
Objective: To test whether an optimal dose of Quillivant XR (methylphenidate extended-release oral suspension [MEROS]) would significantly reduce symptoms of ADHD in children. Method: A randomized, double-blind, placebo-controlled, cross-over, efficacy, safety, and tolerability study of MEROS in 45 children aged 6 to 12 years (open-label dose-optimization phase, followed by double-blind cross-over period). Results: MEROS was significantly more efficacious than placebo during double-blind cross-over laboratory classroom days (Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale and Permanent Product Measure of Performance). During the open-label phase, improvements were observed in scores of ADHD Rating Scale-IV, and Clinical Global Impression-Severity and -Improvement Scales. No occurrences of suicidal ideation or behavior were recorded; the most common open-label treatment-emergent adverse events were typical of stimulant use: decreased appetite, insomnia, and abdominal pain. Conclusion: MEROS was efficacious in the treatment of children aged 6 to 12 years with ADHD, with a safety profile similar to that of other extended-release methylphenidate pharmacotherapies.
Original language | English (US) |
---|---|
Pages (from-to) | 1180-1191 |
Number of pages | 12 |
Journal | Journal of Attention Disorders |
Volume | 21 |
Issue number | 14 |
DOIs | |
State | Published - Dec 1 2017 |
Keywords
- ADHD
- laboratory school
- math test
- methylphenidate
- randomized-controlled trial
ASJC Scopus subject areas
- Developmental and Educational Psychology
- Clinical Psychology